Armstrong, A. J., Geva, R., Chung, H. C., Lemech, C., Miller, W. H., Hansen, A. R., … Wang, J. S. (2024). Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs, 42(3), 340–341. https://doi.org/10.1007/s10637-024-01444-0

Armstrong, Andrew J., Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen, Jong-Seok Lee, et al. “Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.” Invest New Drugs 42, no. 3 (June 2024): 340–41. https://doi.org/10.1007/s10637-024-01444-0.

Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH, Hansen AR, et al. Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs. 2024 Jun;42(3):340–1.

Armstrong, Andrew J., et al. “Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.” Invest New Drugs, vol. 42, no. 3, June 2024, pp. 340–41. Pubmed, doi:10.1007/s10637-024-01444-0.

Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH, Hansen AR, Lee J-S, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs. 2024 Jun;42(3):340–341.